← Russell 3000 cross-section

VKTX Viking Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$3.9bn
Revenue TTM
$0m
Net income TTM
$-535m
Free cash flow
Composite score
Sector rank
#1228

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
Earnings yield vs 10-yr
-18.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-131.0%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-6.27m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.